Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals (Nasdaq: XFOR) will report its Q1 2021 financial results on May 6, 2021. A conference call is scheduled for 8:30 a.m. ET, where updates on recent business highlights will also be discussed. The company is focused on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for Waldenström macroglobulinemia and severe congenital neutropenia. Investors can access the call via phone or live webcast on its website.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 2:15 PM ET. The presentation will focus on their innovative therapies targeting the CXCR4 pathway, particularly the lead candidate, mavorixafor, a unique treatment aimed at rare diseases. A live webcast will be available on the company's website, with an archive accessible for 90 days following the event.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on March 31, 2021, that its Board's Compensation Committee granted inducement awards under the 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase a total of 58,000 shares at an exercise price of $8.61 per share, matching the stock's closing price on the grant date. These options will vest over four years, helping attract new employees to the company. X4 focuses on developing therapies targeting diseases related to the CXCR4 pathway, with its lead candidate being mavorixafor.
X4 Pharmaceuticals (Nasdaq: XFOR) announced a private investment in public equity (PIPE) financing, raising approximately $55 million by selling 6,321,837 shares of common stock at $8.70 per share. New and existing institutional investors participated, including Bain Capital Life Sciences and Abingworth. The funds will support the clinical development of X4's lead candidate, mavorixafor, aimed at treating rare diseases. Following the transaction, X4 intends to file a registration statement with the SEC for resale of shares.
X4 Pharmaceuticals (Nasdaq: XFOR) provided a financial update for Q4 and full year 2020, reporting a net loss of $62.1 million, up from $52.8 million in 2019. The company focuses on its lead candidate, mavorixafor, currently undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for Waldenström’s and SCN. X4 expects to complete enrollment in the WHIM trial in 2021, with data expected in 2022. The company also received Fast Track and Rare Pediatric Designations for mavorixafor from the FDA to address unmet needs in WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021. The announcement includes insights into recent business highlights and will be followed by a conference call at 8:30 a.m. ET. The company specializes in therapies targeting the CXCR4 pathway, with its lead candidate mavorixafor undergoing various clinical trials. X4 aims to address rare diseases and those with limited treatment options, leveraging its expertise at its facilities in Boston and Vienna.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will participate in the B. Riley Oncology Institutional Investor Conference on January 20, 2021, at 11:00 AM ET. The event includes a fireside chat and one-on-one investor meetings. Due to audience limitations, advance registration is required. An archived webcast will be available on the X4 Pharmaceuticals website for 90 days post-event. The company focuses on developing therapies targeting CXCR4 pathway dysfunction, with its lead candidate mavorixafor currently in Phase 3 and Phase 1b clinical trials for various conditions.
X4 Pharmaceuticals (Nasdaq: XFOR) has announced its participation in the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The company's management will present on their innovative therapies targeting CXCR4 pathway dysfunction. An on-demand webcast of the presentation will be accessible on X4's investor website starting January 11, and it will remain available for about 90 days post-conference. X4 is focused on rare diseases with limited treatment options, and its lead candidate, mavorixafor, is currently in pivotal clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on January 4, 2021, that its Board of Directors granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. This includes options to purchase 156,050 shares at an exercise price of $6.43, equal to the stock's closing price on November 30, 2020. The options will vest over four years, contingent on continued employment. X4 focuses on developing therapies targeting diseases from CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, in advanced clinical trials for conditions like WHIM syndrome.
X4 Pharmaceuticals has appointed Diego Cadavid, M.D. as its new Chief Medical Officer. Dr. Cadavid will lead the strategy and execution of the company's clinical development programs. His expertise in advancing therapies for rare and immunological diseases is expected to positively influence ongoing programs, including the Phase 3 trial of mavorixafor for WHIM syndrome. With over 22 years of experience, including roles at Fulcrum Therapeutics and Biogen, Dr. Cadavid aims to leverage his skills to further develop mavorixafor and other preclinical candidates.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
